
Genetic Technologies Limited GENE
Annual report 2022
added 08-30-2022
Genetic Technologies Limited Gross Profit 2011-2026 | GENE
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Genetic Technologies Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -251 K | -111 K | 26.1 K | 81.5 K | 1.12 M | 2.73 M | 1.43 M | 1.74 M | 16.2 M |
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.2 M | -251 K | 2.56 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | ||
|
Brainsway Ltd.
BWAY
|
30.6 M | $ 19.02 | 0.21 % | $ 99.4 M | ||
|
Co-Diagnostics
CODX
|
2.63 M | $ 0.17 | -6.7 % | $ 4.99 M | ||
|
Burning Rock Biotech Limited
BNR
|
364 M | $ 20.15 | -2.3 % | $ 217 M | ||
|
Danaher Corporation
DHR
|
14.2 B | $ 228.92 | -0.76 % | $ 167 B | ||
|
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | ||
|
DexCom
DXCM
|
2.29 B | $ 66.37 | -1.03 % | $ 25.6 B | ||
|
BioNano Genomics
BNGO
|
2.77 M | $ 1.53 | 2.0 % | $ 1.94 M | ||
|
Castle Biosciences
CSTL
|
53 M | $ 38.9 | -1.04 % | $ 1.08 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M | ||
|
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | ||
|
DarioHealth Corp.
DRIO
|
5.98 M | $ 11.38 | 6.36 % | $ 323 M | ||
|
IQVIA Holdings
IQV
|
3.79 B | $ 225.41 | -1.0 % | $ 40.9 B | ||
|
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
493 M | $ 101.56 | -0.33 % | $ 18.8 B | ||
|
Fulgent Genetics
FLGT
|
107 M | $ 26.27 | -0.83 % | $ 794 M | ||
|
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | ||
|
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | ||
|
Myriad Genetics
MYGN
|
585 M | $ 6.15 | -0.32 % | $ 557 M | ||
|
CareDx, Inc
CDNA
|
81.6 M | $ 18.84 | -1.21 % | $ 1.01 B | ||
|
NeoGenomics
NEO
|
290 M | $ 11.76 | -3.84 % | $ 1.49 B | ||
|
National Research Corporation
NRC
|
81.5 M | $ 18.77 | 0.64 % | $ 461 M | ||
|
Anixa Biosciences
ANIX
|
83.8 K | $ 3.12 | - | $ 99.5 K | ||
|
Precipio
PRPO
|
6.02 M | $ 22.98 | -1.84 % | $ 29.8 M | ||
|
Personalis
PSNL
|
22.1 M | $ 7.96 | -0.13 % | $ 472 M | ||
|
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | ||
|
Guardant Health
GH
|
144 M | $ 102.14 | 1.53 % | $ 12.5 B | ||
|
Aspira Women's Health
AWH
|
4.32 M | - | -6.19 % | $ 10.5 M | ||
|
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.53 | -4.83 % | $ 2.43 M | ||
|
Soleno Therapeutics
SLNO
|
-58.5 K | $ 46.3 | 0.02 % | $ 1.86 B | ||
|
Illumina
ILMN
|
2.86 B | $ 131.16 | -1.2 % | $ 20.9 B | ||
|
Charles River Laboratories International
CRL
|
958 M | $ 199.48 | -1.24 % | $ 10.2 B | ||
|
Thermo Fisher Scientific
TMO
|
11.3 B | $ 579.45 | -0.69 % | $ 221 B | ||
|
Trinity Biotech plc
TRIB
|
21.4 M | $ 0.79 | -3.54 % | $ 61.9 M | ||
|
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 173.53 | -1.12 % | $ 19.3 B | ||
|
Biodesix
BDSX
|
18.5 M | $ 6.8 | 1.19 % | $ 882 M | ||
|
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | ||
|
Laboratory Corporation of America Holdings
LH
|
3.62 B | $ 250.88 | -0.87 % | $ 21 B | ||
|
Twist Bioscience Corporation
TWST
|
6.96 M | $ 31.72 | -1.34 % | $ 1.9 B | ||
|
ICON Public Limited Company
ICLR
|
817 M | $ 182.22 | -0.43 % | $ 15 B | ||
|
IDEXX Laboratories
IDXX
|
2.38 B | $ 676.53 | -0.85 % | $ 55.8 B | ||
|
Lantheus Holdings
LNTH
|
988 M | $ 66.55 | -0.91 % | $ 4.61 B |